Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.
Andme report sits at the center of this dementia and brain health question.
The 23andMe Alzheimer’s Genetic Risk Report tests for a single genetic variant—the APOE4 (ε4) version of the APOE gene—which is associated with increased risk for late-onset Alzheimer’s disease. The test cannot diagnose Alzheimer’s and does not mean you will develop the disease if you carry the variant, but it can indicate whether your genetic profile puts you at higher risk. If you have one copy of APOE4, your risk increases by approximately three-fold compared to people without it; if you have two copies, your risk increases eight- to twelve-fold.
Doctors’ opinions on direct-to-consumer genetic testing for Alzheimer’s are cautious but not dismissive. The National Institute on Aging and medical organizations recommend that anyone considering this test—whether through 23andMe or other sources—consult with a doctor or genetic counselor before testing to understand what results mean and how to handle them emotionally and medically. This article explains what the test actually measures, what the risk numbers mean in practical terms, why doctors are careful about how people interpret the results, and what you should do if you’re considering taking the test.
Table of Contents
- How the 23andMe Alzheimer’s Genetic Risk Report Works
- Understanding APOE4 and Relative Risk Numbers
- What Doctors Want You to Know Before Taking the Test
- What the Test Cannot Do
- Other Factors That Influence Alzheimer’s Risk More Than Genetics Alone
- The Practical Question: Should You Get Tested?
- Where Genetic Testing Fits Into Future Alzheimer’s Care
- Conclusion
How the 23andMe Alzheimer’s Genetic Risk Report Works
The 23andMe Alzheimer’s test uses a saliva sample to perform qualitative genotyping on genomic DNA, specifically looking for the apoe4 variant in the APOE gene. The company tests whether you carry zero, one, or two copies of this genetic variant. Your result will tell you your APOE genotype—for example, APOE3/APOE3 (no APOE4 copies), APOE3/APOE4 (one copy), or APOE4/APOE4 (two copies).
The test is straightforward in its mechanics but limited in scope. It examines one genetic risk factor among many that influence Alzheimer’s disease. Some people in their 80s and 90s who carry two copies of APOE4 never develop dementia, while others with no APOE4 copies do. This is why the test gives you a relative risk increase rather than a diagnosis: it’s a single piece of information in a much larger puzzle.
Understanding APOE4 and Relative Risk Numbers
The three-fold and eight-to-twelve-fold risk increases cited in research sound alarming, but they need context to make sense. A three-fold increase doesn’t mean you have a 75% chance of developing Alzheimer’s—it means your risk relative to someone without APOE4 is three times higher. If a 60-year-old without APOE4 has roughly a 7% lifetime risk of Alzheimer’s, a 60-year-old with one copy might have approximately a 21% risk. For those with two copies, the numbers shift further, but the exact risk depends on many other factors.
However, the risk calculations have an important limitation: they were developed and studied most extensively in people of European ancestry, which means the numbers may not apply equally well to people of African, Hispanic, or Asian descent. Research is ongoing to understand how genetic risk factors play out across different populations. Additionally, these are lifetime risks—having a genetic predisposition doesn’t tell you when or if the disease will appear. Some carriers never develop symptoms before other illnesses or age-related causes become the limiting factor in their lifespan.
What Doctors Want You to Know Before Taking the Test
The National Institute on Aging strongly recommends that people considering genetic testing for Alzheimer’s—whether through 23andMe or clinical genetic testing—first speak with a healthcare provider or genetic counselor. This conversation should cover why you want the test, what you hope to do with the results, and how you might react to different outcomes. For example, a 45-year-old woman whose mother developed Alzheimer’s at 60 might decide that knowing her genetic status will help her prioritize heart health, cognitive stimulation, and early screening.
That’s a reasonable use of the information. Another person might feel anxious or fatalistic learning they have APOE4, and for them, the test might do more harm than good without proper counseling and follow-up support. Doctors want to ensure the testing decision fits your psychological needs and medical situation, not just your curiosity.
What the Test Cannot Do
The 23andMe Alzheimer’s report is explicitly not a diagnosis tool. It cannot tell you whether you have Alzheimer’s disease, whether you’ll develop it, or when symptoms might appear. A doctor evaluating someone with actual cognitive concerns follows a different pathway: cognitive testing, medical history review, possible referral to a neurologist or specialist, and potentially imaging (like MRI) and lab tests that look for biomarkers in the blood or cerebrospinal fluid that suggest actual Alzheimer’s pathology in the brain.
This distinction is critical. If you develop actual memory problems or cognitive decline, a positive APOE4 result might be one piece of information your doctor considers, but the diagnosis depends on testing your actual brain function and structure, not just your genes. Conversely, having APOE4 does not mean you should start assuming you have early dementia or seek extensive workups if you’re not experiencing symptoms.
Other Factors That Influence Alzheimer’s Risk More Than Genetics Alone
Age is the single strongest risk factor for Alzheimer’s disease—the risk rises dramatically after age 65. Family history beyond just genetics matters: if multiple close relatives developed Alzheimer’s, your risk is higher, but this could be due to shared genes, shared environment, or both. Sex also plays a role; women make up about two-thirds of people with Alzheimer’s disease, though whether this is purely biological or involves other factors remains an area of research.
The “modifiable risk factors” that doctors emphasize—cardiovascular health, cognitive activity, physical exercise, sleep quality, and diet—may influence whether genetic predisposition leads to actual disease. A person with APOE4 who maintains excellent heart health, stays mentally engaged, exercises regularly, and sleeps well might never develop Alzheimer’s. Conversely, someone without APOE4 who lives a sedentary life with poor sleep and uncontrolled high blood pressure could develop dementia anyway. Your genes set a tendency; your lifestyle, health conditions, and life experiences shape the outcome.
The Practical Question: Should You Get Tested?
Whether to take the 23andMe Alzheimer’s test is a personal decision that depends on your situation and personality. If you have a strong family history of Alzheimer’s and you’re seeking information to guide health decisions, the test might be useful alongside genetic counseling. If you’re already managing cardiovascular risk factors and you want one more data point, it could fit into your overall health strategy.
However, if you’re worried about memory lapses that are actually normal aging, taking the test without professional guidance could amplify anxiety rather than help. If there’s a family history of dementia and it causes emotional distress just to think about it, this isn’t the right test for you at this moment. Some people prefer not to know genetic predisposition information—and that’s a completely valid choice.
Where Genetic Testing Fits Into Future Alzheimer’s Care
Genetic information is becoming more integrated into dementia research and prevention strategies. Studies are now exploring whether people who know they have APOE4 and enroll in preventive interventions—exercise programs, cognitive training, clinical trials for experimental drugs—have better outcomes than those who don’t know. As treatments improve, especially preventive treatments for people without symptoms, knowing your genetic risk might become more medically relevant.
For now, the main value of the test is in motivating or informing lifestyle changes and early medical monitoring if you’re at higher genetic risk. The future may bring blood tests that detect Alzheimer’s-related proteins years before symptoms appear, making genetic risk information part of a much larger picture. Until then, the 23andMe Alzheimer’s report is a conversation-starter with a doctor, not a diagnostic tool.
Conclusion
The 23andMe Alzheimer’s Genetic Risk Report identifies whether you carry copies of the APOE4 variant, which is associated with increased late-onset Alzheimer’s disease risk. One copy increases risk approximately three-fold; two copies increase it eight- to twelve-fold. However, the test cannot diagnose Alzheimer’s disease, and carrying the variant does not guarantee you’ll develop dementia.
Many other factors—age, overall health, lifestyle, family history, and ethnicity—influence whether genetic risk becomes actual disease. If you’re considering this test, consult with a doctor or genetic counselor first to discuss whether it’s right for your situation and to prepare for the results. The test works best as one input into a broader conversation about brain health and preventive measures like cardiovascular care, cognitive engagement, and physical activity. Remember that genetic information is important but not destiny; your lifestyle and health choices may matter just as much as your DNA.
You Might Also Like
- The Free Dementia Risk Calculator That Tells You Your 10 Year Risk in Under 5 Minutes
- The Genetic Test for Dementia Risk That Costs $100 and Is Now Available Without a Doctor Order
- Why Having the APOE4 Gene Does Not Mean You Will Definitely Get Alzheimer’s Disease
For more, see CDC — Alzheimer’s and Dementia.
